IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and biomarker analytics company, has announced a technology collaboration with Medidata, a Dassault Systèmes brand and leading provider of clinical trial software to the life sciences industry.
The partnership will integrate IXICO's IXI Platform with the Medidata Platform, creating a unified neuroimaging data and analysis system for biopharma companies running clinical trials in neurological disorders.
The combined offering is designed to streamline reporting of patient eligibility and safety criteria, while enabling the collection, upload, management, and analysis of complex neuroimaging data within a regulatory-compliant environment.
IXICO said the agreement is expected to broaden its market reach, create opportunities for technological co-development, and provide an additional commercial route beyond its existing direct client relationships.
The deal is non-exclusive, meaning IXICO will continue to contract independently with biopharma clients and pursue other partnership opportunities outside of any joint activities with Medidata.
Bram Goorden, chief executive of IXICO, said the agreement supports the company's strategy to extend the reach of its platform and analytics capabilities to biopharma customers at scale.
Wayne Walker, senior vice president of data experience at Medidata, said the collaboration would expand both companies' impact in central nervous system (CNS) clinical trials and empower contract research organisations (CROs) to deliver a superior experience to their biopharma sponsors.
CNS drug development is one of the most data-intensive areas of clinical research, with neuroimaging playing a central role in assessing treatment eligibility, disease progression, and safety outcomes across conditions such as Alzheimer's disease and Parkinson's disease.
IXICO has positioned its AI-driven platform as a specialist tool for biopharma companies seeking to accelerate drug development programmes targeting neurological conditions.